The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / California Rheumatologists Explore Managed Care, Treatment Options

California Rheumatologists Explore Managed Care, Treatment Options

July 9, 2012 • By Larry Beresford

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Dr. Keystone also discussed other composite indices for assessing RA, including the RAPID3 (routine assessment of patient index data), which he believes is a predictor of radiologic progression.3 “TSS [Total Sharp Score] means less than the probability of radiologic progression and may lead you astray,” he said, because a substantial change in TSS is needed to register any noticeable change in physical functioning.

You Might Also Like
  • RA Treatment Options: Researchers Explore Groundwork for New Therapies
  • Data-Driven, Optimal Patient Care and Clinical Research
  • 2013 ACR/ARHP Annual Meeting: Researchers Explore Role of Pathogens, Quality of Care in Rheumatoid Arthritis
Explore This Issue
July 2012
Also By This Author
  • Janus Kinase vs. TNF Inhibitors: The Context for Venous Thromboembolism Risk with RA Treatments

He reviewed several landmark studies showing benefits of combined therapies, infliximab, adalimumab, or etanercept with methotrexate, for patients at various stages of disease progression. He pointed out that RA patients today tend to be seen earlier in their disease progression, with more moderate symptoms, and receive higher doses of methotrexate than in the past.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Hot Topics in Osteoporosis Treatment Reviewed

Paul Miller, MD, CCD, medical director of the Colorado Center for Bone Research, reviewed a number of current topics in osteoporosis treatment, including the issue of drug “holidays” from bisphosphonate treatments. He outlined these drugs’ unusual properties; for example, that they are not metabolized by the body. Half of the treatment binds to the bone while half is secreted by the kidney. Uptake, retention, and detachment of the drug from bone surfaces continue during treatment and beyond, at different rates of detachment for different bisphosphonates, and when recycled into the bloodstream, the drugs are still biologically active. These properties “allow us to consider a break from treatment,” he said.

Drug holidays from bisphosphonates are not the current standard of care in the United States, despite concerns about potential long-term side effects, Dr. Miller said. On September 11, 2011, the Food and Drug Administration (FDA) convened an advisory panel to consider whether it should change its prescribing label for bisphosphonates. The committee opted not to make a change at this time, acknowledging that there is no consensus to support regulatory restriction on duration of drug use, although it recommended that the labeling be updated. The FDA continues to express concerns about long-term safety and efficacy, with limited data to demonstrate the effectiveness of these treatments beyond five years.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Recently in the New England Journal of Medicine, the FDA reviewed its concerns about duration of bisphosphonate use for achieving and maintaining protection against fracture while minimizing rare but serious adverse events associated with these drugs, such as atypical fractures, osteonecrosis of the jaw, esophageal cancer, and atrial fibrillation.4,5 The evidence is clear that bisphosphonate treatment for three or four years is effective in reducing vertebral and nonvertebral fractures in osteoporotic women, although the optimal duration of treatment remains controversial. In both NEJM articles and other recent reviews on bisphosphonate benefit–risk ratios, there seems to be a consensus emerging that drug holidays in high-risk patients may be associated with a greater risk of subsequent fractures, Dr. Miller said.6,7 “High risk” is defined as the preexistence of a low trauma fracture or a femoral neck T-score of -2.5 or lower.

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Career Development, Education & Training, Legislation & Advocacy, Professional Topics, Research Reviews Tagged With: ACA, Affordable Care Act, Biologics, drug, Healthcare Reform, Legislation, Lupus, managed care, Medicare, Osteoporosis, patient care, radiograph, Research, Rheumatoid arthritis, rheumatologist, Systemic lupus erythematosusIssue: July 2012

You Might Also Like:
  • RA Treatment Options: Researchers Explore Groundwork for New Therapies
  • Data-Driven, Optimal Patient Care and Clinical Research
  • 2013 ACR/ARHP Annual Meeting: Researchers Explore Role of Pathogens, Quality of Care in Rheumatoid Arthritis
  • A&R and AC&R Abstracts: Bisphosphonates

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.